Compare Icl Group Ltd (ICL) vs Revvity Inc (RVTY) Price & Performance

ICL trades at $5.08 with no recent price movement. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported $7.15B revenue in 2025 with a 3.95% net margin, while valuation ratios appear reasonable with P/E of 20.83 and P/S of 0.84. Recent earnings showed Q2 2026 beat expectations with $0.12 EPS versus $0.11 expected. The company maintains stable cash flow generation despite recent net cash outflows.

ICL presents a cautious opportunity with 19.7% upside to the $6.08 consensus price target, though analyst sentiment is neutral with 100% hold ratings. Key risks include fertilizer industry headwinds from higher input costs and competitive pressures. The dividend yield of approximately 1.2% provides income support while investors await earnings recovery toward projected 2026 profitability improvement.

Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.

The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.